Literature DB >> 26998037

β-catenin knockdown inhibits the proliferation of human glioma cells in vitro and in vivo.

Zhong Wang1, Qianxue Chen1.   

Abstract

β-catenin is a crucial oncogene that is capable of regulating cancer progression. The aim of the present study was to clarify whether β-catenin was associated with the proliferation and progress of glioma. In order to knockdown the expression of β-catenin in human U251 glioma cells, three pairs of small interfering (si)RNA were designed and synthesized and the most effective siRNA was selected and used for silencing the endogenous β-catenin, which was detected by western blot analysis and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Proliferation was subsequently detected using a methylthiazolyl-tetrazolium bromide assay and the results demonstrated that knockdown of β-catenin significantly inhibited the proliferation of U251 cells in a time- and dose-dependent manner (P<0.01). Cell apoptosis rate was analyzed using flow cytometry and Annexin V-fluorescein isothiocyanate/propidium iodide staining demonstrated that β-catenin siRNA significantly increased the apoptosis of U251 cells (P<0.01). Furthermore, the results of an in vitro scratch assay demonstrated that β-catenin silencing suppressed the proliferation of U251 cells, as compared with the control group (P<0.01). In vivo, β-catenin expression levels in U251 cells were significantly inhibited (P<0.01) following β-catenin short hairpin (sh)RNA lentiviral-vector transfection, as detected by western blot analysis and RT-qPCR. Tumorigenicity experiments demonstrated that β-catenin inhibition significantly increased the survival rate of nude mice. The results of the present study demonstrated that knockdown of β-catenin expression significantly inhibited the progression of human glioma cancer cells, in vitro and in vivo; thus suggesting that β-catenin silencing may be a novel therapy for the treatment of human glioma.

Entities:  

Keywords:  glioma cancer; interference; proliferation; β-catenin

Year:  2016        PMID: 26998037      PMCID: PMC4774551          DOI: 10.3892/etm.2016.2998

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  24 in total

1.  Optic nerve glioma: case series with review of clinical, radiologic, molecular, and histopathologic characteristics.

Authors:  Lora R Dagi Glass; Peter Canoll; Angela Lignelli; Azra H Ligon; Michael Kazim
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2014 Sep-Oct       Impact factor: 1.746

Review 2.  The epidemiology of glioma in adults: a "state of the science" review.

Authors:  Quinn T Ostrom; Luc Bauchet; Faith G Davis; Isabelle Deltour; James L Fisher; Chelsea Eastman Langer; Melike Pekmezci; Judith A Schwartzbaum; Michelle C Turner; Kyle M Walsh; Margaret R Wrensch; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2014-07       Impact factor: 12.300

3.  Incidence and management of high grade glioma in Māori and non-Māori patients.

Authors:  Hamish Alexander; Chris Irwin; Gordon Purdie; Martin Hunn
Journal:  J Clin Neurosci       Date:  2010-06-23       Impact factor: 1.961

Review 4.  Photodynamic therapy of cerebral glioma - a review. Part II - clinical studies.

Authors:  Stanley S Stylli; Andrew H Kaye
Journal:  J Clin Neurosci       Date:  2006-03-29       Impact factor: 1.961

Review 5.  Genetics of adult glioma.

Authors:  McKinsey L Goodenberger; Robert B Jenkins
Journal:  Cancer Genet       Date:  2012-12-11

Review 6.  The art of gene therapy for glioma: a review of the challenging road to the bedside.

Authors:  Alex Tobias; Atique Ahmed; Kyung-Sub Moon; Maciej S Lesniak
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-09-19       Impact factor: 10.154

7.  Use of the MTT assay for estimating toxicity in primary astrocyte and C6 glioma cell cultures.

Authors:  M R Cookson; C Mead; S M Austwick; V W Pentreath
Journal:  Toxicol In Vitro       Date:  1995-02       Impact factor: 3.500

Review 8.  CpG-oligonucleotides for cancer immunotherapy : review of the literature and potential applications in malignant glioma.

Authors:  Antoine F Carpentier; Gregor Auf; Jean-Yves Delattre
Journal:  Front Biosci       Date:  2003-01-01

9.  Nuclear GSK-3beta inhibits the canonical Wnt signalling pathway in a beta-catenin phosphorylation-independent manner.

Authors:  M Caspi; A Zilberberg; H Eldar-Finkelman; R Rosin-Arbesfeld
Journal:  Oncogene       Date:  2008-01-28       Impact factor: 9.867

Review 10.  Review: on TRAIL for malignant glioma therapy?

Authors:  J M A Kuijlen; E Bremer; J J A Mooij; W F A den Dunnen; W Helfrich
Journal:  Neuropathol Appl Neurobiol       Date:  2010-01-20       Impact factor: 8.090

View more
  3 in total

1.  Expression profile and clinical significance of Wnt signaling in human gliomas.

Authors:  Hao Zhang; Yanhua Qi; Decheng Geng; Yi Shi; Xu Wang; Rutong Yu; Xiuping Zhou
Journal:  Oncol Lett       Date:  2017-11-01       Impact factor: 2.967

2.  RBM5 inhibits tumorigenesis of gliomas through inhibition of Wnt/β-catenin signaling and induction of apoptosis.

Authors:  Yuanpei Jiang; Hongling Sheng; Lei Meng; Hongsheng Yue; Bo Li; Aijun Zhang; Yanan Dong; Yuguang Liu
Journal:  World J Surg Oncol       Date:  2017-01-06       Impact factor: 2.754

3.  Knockdown of Collagen Triple Helix Repeat Containing 1 (CTHRC1) Inhibits Epithelial-Mesenchymal Transition and Cellular Migration in Glioblastoma Cells.

Authors:  Jianpeng Liu; Wei Li; Shunshun Liu; Xu Zheng; Lin Shi; Weitao Zhang; Hongfa Yang
Journal:  Oncol Res       Date:  2017-01-26       Impact factor: 5.574

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.